The purpose of this study is to explore the ability of positron emission tomography (PET) with \[68Ga\]FAPI to detect, evaluate treatment response, and predict prognosis in advanced liver and biliary cancer patients treated with anti-PD-1 antibodies-based combination therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Baseline SUVmax on [68Ga]FAPI and [18F] FDG PET Scans
Timeframe: through study completion, an average of 2 years
Baseline active tumor volume on [68Ga]FAPI and [18F] FDG PET Scans
Timeframe: through study completion, an average of 2 years
Baseline total lesion activation on [68Ga]FAPI and [18F] FDG PET Scans
Timeframe: through study completion, an average of 2 years
Response of SUVmax to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans
Timeframe: through study completion, an average of 1 years
Response of active tumor volume to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans
Timeframe: through study completion, an average of 1 years
Response of total lesion activation to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans
Timeframe: through study completion, an average of 1 years